Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.45 |
| ▸ | PTGIR | P43119 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 7/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 7/20 | 0.38 |
| ▸ | EP300 | Q09472 | 5/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4706484 | 0.92 | PDE4A (0.52) | PDE4APDE4BPTGIRMCHR1BRD4 | |
| SCHEMBL4708697 | 0.90 | BRD4 (0.46) | PDE4BPTGIRBRD4CREBBPEP300 | |
| SCHEMBL4708948 | 0.89 | PDE4B (0.58) | PDE4APDE4BMCHR1PARP1POLB | |
| SCHEMBL4708038 | 0.88 | PDE4B (0.54) | PDE4APDE4BPTGIRMCHR1BRD4 | |
| SCHEMBL4708332 | 0.87 | PDE4B (0.46) | PDE4BMCHR1BRD4CREBBPEP300 | |
| SCHEMBL4708006 | 0.86 | PDE4A (0.47) | PDE4APDE4BPTGIRMCHR1BRD4 | |
| SCHEMBL3033400 | 0.86 | PDE4A (0.52) | PDE4APDE4BPTGIRMCHR1BRD4 | |
| SCHEMBL4706429 | 0.85 | PDE4B (0.49) | PDE4APDE4BPTGIRMCHR1BRD4 | |
| SCHEMBL6167315 | 0.84 | PDE4B (0.44) | PDE4BPTGIRBRD4CREBBPEP300 | |
| SCHEMBL3032464 | 0.84 | PDE4A (0.46) | PDE4APDE4BPTGIRMCHR1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269235-A1 | PYRIDAZIN-3 (2H) -ONE DERIVATIVES AS PDE4 INHIBITORS | DAL PIAZ VITTORIO | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269235-A1 | PYRIDAZIN-3 (2H) -ONE DERIVATIVES AS PDE4 INHIBITORS | PDE4A, PDE3A, PDE4B | PDE4A 1/4885PDE4B 3/4885PTGIR 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.